The review shows that exenatide seemed to decrease the heavy drinking days in obese people through its effect on the brain areas controlling drug reward and addiction (Klausen et al 37 )
Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S
individual complications
For pharma, it is a once-in-a-generation opportunity To redefine obesity from a stigma to a treatable, chronic disease with measurable ROI for patients and payers
This quantity allows researchers to prepare solutions at different dilutions for in vitro assays, such as cell migration studies, or in vivo dosing in animal models, enabling precise titration in preclinical investigations
Nature medicine , 28(10), 20832091